Hasil untuk "Costs"

D. Leslie, E. Marcantonio, Ying Zhang et al.

BACKGROUND While delirium has been increasingly recognized as a serious and potentially preventable condition, its long-term implications are not well understood. This study determined the total 1-year health care costs associated with delirium. METHODS Hospitalized patients aged 70 years and older who participated in a previous controlled clinical trial of a delirium prevention intervention at an academic medical center between 1995 and 1998 were followed up for 1 year after discharge. Total inflation-adjusted health care costs, calculated as either reimbursed amounts or hospital charges converted to costs, were computed by means of data from Medicare administrative files, hospital billing records, and the Connecticut Long-term Care Registry. Regression models were used to determine costs associated with delirium after adjusting for patient sociodemographic and clinical characteristics. RESULTS During the index hospitalization, 109 patients (13.0%) developed delirium while 732 did not. Patients with delirium had significantly higher unadjusted health care costs and survived fewer days. After adjusting for pertinent demographic and clinical characteristics, average costs per day survived among patients with delirium were more than 2(1/2) times the costs among patients without delirium. Total cost estimates attributable to delirium ranged from $16 303 to $64 421 per patient, implying that the national burden of delirium on the health care system ranges from $38 billion to $152 billion each year. CONCLUSIONS The economic impact of delirium is substantial, rivaling the health care costs of falls and diabetes mellitus. These results highlight the need for increased efforts to mitigate this clinically significant and costly disorder.

G. Bonanno, C. Brewin, K. Kaniasty et al.

R. Scott

G. Barbash, S. Glied

A. Dixon

R. Naidoo, A. Balmford, Paul J. Ferraro et al.

M. Y. Bartlett, D. Desteno

A. Falk, M. Kosfeld

D. Reznick

T. Hoshi, Anil K. Kashyap, D. Scharfstein et al.

J. Sutton

Jerold B. Warner

M. Koopmanschap, L. Roijen

J. Newhouse

R. Tol

Emily Oshima Lee, E. Emanuel

Clara Xiaoling Chen, Hai-fan Lu, Theodore Sougiannis

Prior studies have documented the asymmetrical behavior of selling, general and administrative (SG&A) costs (i.e., SG&A costs increase more when activity rises than they decrease when activity falls), and have explained this phenomenon primarily with economic factors. Drawing on agency theory, we argue that SG&A cost asymmetry is driven not only by economic factors but also by the agency problem which causes a shift in SG&A cost asymmetry away from its optimal level. Using data for S&P 1500 firms over the period 1996–2005, we find that the degree of SG&A cost asymmetry is positively associated with managers’ empire building incentives due to the agency problem (measured by free cash flow and CEO horizon, tenure, and compensation structure), suggesting that the agency problem provides an additional explanation for SG&A cost asymmetry. Moreover, we find that strong corporate governance mitigates the positive association between the agency problem and the degree of SG&A cost asymmetry. In additional analyses, we also find that the agency problem influences cost stickiness to a greater extent in mature firms and in firms where SG&A costs create low future value.

A. Melnyk, A. Wong, R. Kassen

Antibiotic resistance is increasing in pathogenic microbial populations and is thus a major threat to public health. The fate of a resistance mutation in pathogen populations is determined in part by its fitness. Mutations that suffer little or no fitness cost are more likely to persist in the absence of antibiotic treatment. In this review, we performed a meta‐analysis to investigate the fitness costs associated with single mutational events that confer resistance. Generally, these mutations were costly, although several drug classes and species of bacteria on average did not show a cost. Further investigations into the rate and fitness values of compensatory mutations that alleviate the costs of resistance will help us to better understand both the emergence and management of antibiotic resistance in clinical settings.

Robert Novy-Marx, Mihail Velikov

Ismail Kimuli, John Baptist Kirabira

Kampala faces increasing congestion, air pollution, and dependence on fossil fuels, driven by widespread reliance on diesel minibuses and motorcycle taxis. Existing models—KAMPALA-TIMES, KLAP-TIMES, and GKMA-TIMES–CGE—show strong potential for electrified mass transit to reduce emissions, change commuter behavior, and boost macroeconomic welfare. However, these studies assume electric-bus reliability without examining the mechanical conditions needed to achieve their projected outcomes. This study combines system-level modeling insights with vehicle-level engineering analysis to identify key mechanical factors necessary for the successful deployment of electric Bus Rapid Transit (e-BRT) in Kampala. It considers drivetrain torque for steep gradients, battery thermal management in hot equatorial climates, and regenerative braking efficiency in traffic congestion, alongside policy, infrastructure, and grid readiness. Mechanical performance links modeling to implementation—adequate torque, thermal stability, and regenerative braking efficiency directly affect service reliability, headway adherence, fleet uptime, and lifecycle costs. These operational factors influence commuter mode choices, the realism of bottom-up pathways, and the broader economic benefits predicted in top-down scenarios. Engineering reliability must be a core policy consideration, guiding procurement standards, charging infrastructure design, and multisector coordination among KCCA, MoWT, MEMD, and Uganda’s power utilities. Incorporating mechanical parameters into future bottom-up or hybrid models, combined with digital-twin testing and degradation-aware analytics, will enable Kampala to serve as a living laboratory for low-carbon mobility transitions across Sub-Saharan Africa.